• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Fitzpatrick Jennifer

    4/1/25 4:05:16 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SION alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Fitzpatrick Jennifer

    (Last) (First) (Middle)
    SIONNA THERAPEUTICS, INC.
    21 HICKORY DRIVE, SUITE 500

    (Street)
    WALTHAM MA 02451

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/01/2025
    3. Issuer Name and Ticker or Trading Symbol
    Sionna Therapeutics, Inc. [ SION ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Legal Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) (1) 07/14/2034 Common Stock 147,149 $6.11 D
    Stock Option (Right to Buy) (2) 02/05/2035 Common Stock 120,686 $18 D
    Explanation of Responses:
    1. 25% of the shares underlying this option shall vest on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
    2. The shares underlying this option vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.
    Remarks:
    Exhibit 24 - Power of Attorney.
    /s/ Jennifer Fitzpatrick, Attorney-in-Fact 04/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SION alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SION

    DatePrice TargetRatingAnalyst
    3/4/2025Buy
    TD Cowen
    3/4/2025$32.00Buy
    Stifel
    3/4/2025$45.00Buy
    Guggenheim
    More analyst ratings

    $SION
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Sionna Therapeutics

      TD Cowen initiated coverage of Sionna Therapeutics with a rating of Buy

      3/4/25 8:27:05 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Sionna Therapeutics with a new price target

      Stifel initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $32.00

      3/4/25 7:43:40 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Sionna Therapeutics with a new price target

      Guggenheim initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $45.00

      3/4/25 7:43:20 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SION
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sionna Therapeutics Reports First Quarter 2025 Financial Results

      Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Strong cash position following completed upsized IPO, with approximately $354.7 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for c

      5/12/25 7:00:00 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

      WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 12:30 p.m. ET. A live webcast of the presentation will be available the day of the event on the "Events" page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will be available for 90

      4/30/25 7:00:00 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025 On track to initiate NBD1 Phase 2a proof-of-concept trial in combination with SOC in CF patients and combination MAD trials of an NBD1 stabilizer with a complementary modulator in healthy volunteers in the second half of 2025, with topline data for both anticipated in mid-2026 Completed upsized IPO with gross proceeds of approximately $219 million, extending runway into 2028 WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, I

      3/20/25 7:00:00 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SION
    SEC Filings

    See more
    • SEC Form 10-Q filed by Sionna Therapeutics Inc.

      10-Q - Sionna Therapeutics, Inc. (0002036042) (Filer)

      5/12/25 7:31:04 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sionna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)

      5/12/25 7:12:56 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Sionna Therapeutics Inc.

      DEFA14A - Sionna Therapeutics, Inc. (0002036042) (Filer)

      4/29/25 7:31:12 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SION
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tpg Gp A, Llc converted options into 4,875,547 shares and bought $20,250,000 worth of shares (1,125,000 units at $18.00) (SEC Form 4)

      4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

      2/12/25 5:21:33 PM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SION
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Fitzpatrick Jennifer

      3 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

      4/1/25 4:05:16 PM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Tpg Gp A, Llc converted options into 4,875,547 shares and bought $20,250,000 worth of shares (1,125,000 units at $18.00) (SEC Form 4)

      4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

      2/12/25 5:21:33 PM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care